Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.Sales of ...

The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine — the nation's only traditional protein-based option for the coronavirus — is sowing uncertainty about ...